Novel triazole antifungal agents

Bibliography

• PFALLER MA, JONES RN, MESSER SAet al.: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiol-ogic. Diagn. Microbial. Infect. Dis. (1998) 30:121-129.
   Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ et al: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. (1999) 33:217–222.
   Google Scholar
• REX JH, RINALDI MG, PFALLER MA: Resistance ofCandida species to fluconazole. Antimicrob. Agents Chemother. (1995) 39:1–8.
   PubMed Web of Science ®Google Scholar
• MAENZA JR, MERZ WG, ROMAGNOLI MJ et al.: Infectiondue to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin. Infect. Dis. (1997) 24:28–34.
   PubMed Web of Science ®Google Scholar
• TROKE PF, BELL AS, DICKINSON RP et al: UK-109,496, Anovel, wide-spectrum triazole derivative for the treatment of fungal infection: Discovery and Antifungal properties. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F69.
   Google Scholar
• RICHARDSON K, BELL AS, DICKINSON RP et al.:UK-109,496, A novel, wide-spectrum triazole deriva-tive for the treatment of fungal infections: Synthesis and SAR. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F69.
   Google Scholar
• PATTERSON BE, COATES PE: UK-109,496, A novel,wide-spectrum triazole derivative for the treatment of fungal infection: Pharmacokinetics in man. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (1995). Abstract F78.
   Google Scholar
• TROKE PF, BRAMMER KW, HITCHCOCK CA et al.:UK-109,496, A novel, wide-spectrum triazole deriva-tive for the treatment of fungal infections: Activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis. 35th Intel-science Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F73.
   Google Scholar
• DUPONT B, DENNING D, LODE H et al.: UK-109,496, Anovel, wide-spectrum triazole derivative for the treatment of fungal infection: Clinical efficacy in chronic invasive Aspergillosis. 35th Intel-science Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F81.
   Google Scholar
• DENNING D, DEL FAVERO A, GLUCKMAN E et al.: UK-109,496, A novel, wide-spectrum triazole deriva-tive for the treatment of fungal infection: Clinical effecacy in acute invasive Aspergillosis. 35th Intersci-ence Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (1995). Abstract F80.
   Google Scholar
• SCHWARTZ S, MILATOVIC D, THIEL E: Successfultreatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia [see comments]. Br. J. Haematol. (1997) 97:663–665.
   PubMed Web of Science ®Google Scholar
• •Successful case report with use of voriconazole.
   Google Scholar
• PATTERSON BE, ROFFEY S, JEZEQUEL SG et al.:UK-109,496, A novel, wide-spectrum triazole deriva-tive for the treatment of fungal infection: Disposition in man. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F70.
   Google Scholar
• NOMEIR AA, KUMARI P, GUPTA S et al.: Pharmacoki-netics of SCH 59884, an IV prodrug for the oral antifungal SCH 56592 in animals, and its conversion to Sch 56592 by human tissues. 39th Intel-science Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999). Abstract 1934.
   Google Scholar
• LOEBENBERG D, MENZEL F, CORCORAN E et al.: SCH 59884, the intravenous prodrug of the antifungal trazole SCH 56592. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999). Abstract 1933.
   Google Scholar
• GIRIJAVALLABHAN VM, BENNETT F, SAKSENA AK et al.: SCH 59884, a water-soluble prodrug of SCH 56592 for intravenous formulation. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999). Abstract 1932.
   Google Scholar
• NOMEIR A, KUMARI P, HILBERT MJ et al.: Comparative pharmacokinetics of a new triazole antifungal agent, SCH 56592, in mice, rats, rabbits, dogs and cynomolgus monkeys. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F68.
   Google Scholar
• THONOOR M, GUPTA S, SOLON E et al.: Pharmacoki-netics of 14C-SCH 56592 in rats and dogs. 37th Intel-sci-ence Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada (1997). Abstract A–85.
   Google Scholar
• RADWANSKI E, KOSOGLOU T, LIM J et al.: SCH 56592: Bioavailability of an oral suspension relative to a solid dosage form in healthy volunteers. 37th Intel-science Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (1997). Abstract A–86.
   Google Scholar
• LAUGHLIN M, PAI S, MENON S: SCh 56592: Rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in health volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (1997). Abstract A–75.
   Google Scholar
• KRIETER P, ACHANFUO-YEBOAH J, SHEA M et al.: Biliary excretion an enterohepatic circulation of the antifungal agent 14C-SCH 56592 in male and female rats. 39th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999). Abstract 1199.
   Google Scholar
• NAKAMURA T, SAKAI R, SONODA J et al.: ER-30346, a novel antifungal triazole: IV pharmacokinetic and toxicological studies in mice, rats and dogs. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F94.
   Google Scholar
• HATA K, KIMURA J, MIKI H et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40:2237–2242.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ etal.: In vitro suscep-tibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother. (1998) 42:3242–3244.
   Google Scholar
• ••Published data comparing voriconazole, posaconazole andravuconazole. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(3)
   Google Scholar
• DIEKEMA DJ, PFALLER MA, MESSER SA et al: In vitro Activities of BMS-207147 against Over 600 Contempo-rary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. (1999) 43:2236–2239.
   PubMed Web of Science ®Google Scholar
• RUHNKE M, SCHMIDT-WESTHAUSEN A, TRAUTMANN M: In vitro activities of voriconazole (UK-109,496) against fluconazole- susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1997) 41:575–577.
   PubMed Web of Science ®Google Scholar
• BELANGER P, NAST CC, FRATTI R et al.: Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:1840–1842.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN CA, ZARINS LT: In vitro activity of voricona-zole against Candida species. Diagn. Microbic)]. Infect. Dis. (1998) 31:297–300.
   PubMed Web of Science ®Google Scholar
• BARRY AL, BROWN SD: In vitro studies of two triazole antifungal agents (voriconazole [UK- 109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. (1996) 40:1948–1949.
   PubMed Web of Science ®Google Scholar
• MARCO F, PFALLER MA, MESSER S et al.: In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. (1998) 42:161–163.
   PubMed Web of Science ®Google Scholar
• LAW D, MOORE CB, DENNING DW: Activity of SCH56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. (1997) 41:2310–2311.
   PubMed Web of Science ®Google Scholar
• NGUYEN MH, YU CY: Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. (1998) 42:253–256.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC JC, HUCZKO E, MINASSIAN B et al.: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42:313–318.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, GEE S et al.: In vitro suscepti-bilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. Clin. Microbic)]. (1999) 37:870–872.
   PubMed Web of Science ®Google Scholar
• SANATI H, BELANGER P, FRATTI R et al.: A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob. Agents Chemother. (1997) 41:2492–2496.
   PubMed Web of Science ®Google Scholar
• MUNAYYER H, SHAW KJ, HARE RS et al.: SCH 56592 is a potent inhibitor of sterol C14 demethylation in fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, USA (1996). Abstract F92.
   Google Scholar
• GHANNOUM MA, OKOGBULE-WONODI I, BHAT N et al.: Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematoge-nous Candida krusei infection in neutropenic guinea pig model. J. Chemother. (1999) 11:34–39.
   PubMed Web of Science ®Google Scholar
• CACCIAPUOTI A, PARMEGIANI R, LOEBENBERG D et al.:Efficacy of SCH 56592 in pulmonary Aspergillosis and Candidiasis in mice. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1995). Abstract F66.
   Google Scholar
• COLEMAN JM, HOGG GG, ROSENFELD JV et al: Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery, case report and review of the literature. Neurosurgery (1995) 36:858–863.
   PubMed Web of Science ®Google Scholar
• VON EIFF M, ROOS N, SCHULTEN R et al.: Pulmonary aspergillosis: early diagnosis improves survival. Respiration (1995) 62:341–347.
   PubMed Web of Science ®Google Scholar
• ABRAHAM OC, MANAVAATHU EK, CUTRIGHT JL et al.: In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn. Microbiol Infect. Dis. (1999) 33:7–11.
   PubMed Web of Science ®Google Scholar
• MURPHY M, BERNARD EM, ISHIMARU T et al.: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experi-mental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. (1997) 41:696–698.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J. Antimicrob. Chemother. (1998) 42:91–94.
   Google Scholar
• WILDFEUER A, SEIDL HP, PAULE I et al.: In vitro evalua-tion of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses (1998) 41:309–319.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. (1997) 41:1124–1126.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL A: Efficacy of SCH 56592 in treatment and prevention of invasive pulmonary Aspergillosis in persistently neutropenic rabbits. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999). Abstract 2004.
   Google Scholar
• MARTIN MV, YATES J, HITCHCOCK CA: Comparison ofvoriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. (1997) 41:13–16.
   PubMed Web of Science ®Google Scholar
• VAN HEK LG, VERWEIJ PE, WEEMAES CM etal.: Successfultreatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am. J. Respir. Grit. Care Med. (1998) 157:1694–1696.
   Google Scholar
• •Successful case report with use of voriconazole.
   Google Scholar
• KLEPSER ME, WOLFE EJ, JONES RN et al.: Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. (1997) 41:1392–1395.
   PubMed Web of Science ®Google Scholar
• KLEPSER ME, WOLFE EJ, PFALLER MA: Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J. Antimicrob. Chemother. (1998) 41:397–401.
   PubMed Web of Science ®Google Scholar
• MALONE D, LEWIS R, ERNST E et al: Evaluation ofvoriconazole pharmacodynamic activity using time-kill methodology. International Congress on Clinical Pharmacy. Orlando, FL, USA (1999). Abstract 84.
   Google Scholar
• LEVITZ SM: The ecology of Cryptococcus neoformansand the epidemiology of cryptococcosis. Rev. Infect. Dis. (1991) 13:1163–1169.
   PubMedGoogle Scholar
• PFALLER MA, ZHANG J, MESSER SA et al.: In vitro activi-ties of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neofor-mans from the United States and Africa. Antimicrob. Agents Chemother. (1999) 43:169–171.
   PubMed Web of Science ®Google Scholar
• PERFECT JR, COX GM, DODGE RK et al.: In vitro and invivo efficacies of the azole SC1156592 against Crypto-coccus neoformans. Antimicrob. Agents Chemother. (1996) 40:1910–1913.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: In vitro activity of the new triazolevoriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36:198–202.
   PubMed Web of Science ®Google Scholar
• MCGINNIS MR, PASARELL L, SUTTON DA et al.: In vitroevaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. (1997) 41:1832–1834.
   PubMed Web of Science ®Google Scholar
• SUGAR AM, LIU XP: In vitro and in vivo activities of SCH56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. (1996) 40:1314–1316.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT J, SCHNIZLEIN-BICK C et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. (1999) 43:322–328.
   PubMed Web of Science ®Google Scholar
• LUTZ JE, CLEMONS KV, ARISTIZABAL BH et al.: Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. (1997) 41:1558–1561.
   PubMed Web of Science ®Google Scholar
• MARCO F, PFALLER MA, MESSER SA et al.: Antiftmgal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med. Mycol. (1998) 36:433–436.
   PubMed Web of Science ®Google Scholar
• GIRMENIA C, LUZI G, MONACO M et al.: Use of voricona-zole in treatment of Scedosporium apiospermum infection: case report. J. Clin. Microbiol (1998) 36:1436–1438.
   PubMed Web of Science ®Google Scholar
• •Successful case report with use of voriconazole.
   Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL et al.: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43:589–591.
   PubMed Web of Science ®Google Scholar
• Fluconazole package insert. New York NY. Pfizer, Inc. (1996).
   Google Scholar
• Itraconazole package insert. Titusville, NJ. Janssen Pharmaceutica, Inc. (1997).
   Google Scholar
• HOBAN DJ, ZHANEL GG, KARLOWSKY JA: In vitro susceptibilities of Candida and Cryptococcus neofor-mans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother. (1999) 43:1463–1464.
   PubMed Web of Science ®Google Scholar